Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1394&sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1395&sort=other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=other_investigators" }, "data": [ { "type": "Grant", "id": "7490", "attributes": { "award_id": "3UL1TR002389-04S3", "title": "ITM 2.0: Advancing Translational Science in Metropolitan Chicago", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-06", "end_date": "2022-06-30", "award_amount": 1741474, "principal_investigator": { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23290, "first_name": "Lainie Friedman", "last_name": "Ross", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23291, "first_name": "Julian", "last_name": "Solway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.", "keywords": [ "Academic Medical Centers", "Acute", "Advocate", "Anti-Inflammatory Agents", "Award", "Biotechnology", "COVID-19", "Case Series", "Cessation of life", "Chicago", "Chronic", "Clinical Research", "Clinical Sciences", "Collaborations", "Communities", "Consumption", "Data", "Diet", "Disease", "Dose", "Eating", "Effectiveness", "Elderly", "Ethics", "Exposure to", "Failure", "Fishes", "General Population", "Goals", "Health", "Health Personnel", "Healthcare", "Home environment", "Hospitalization", "Hour", "Human", "Hypercalcemia", "Illinois", "Industry", "Infection", "Inflammatory", "Infrastructure", "Institute of Medicine (U.S.)", "Institutes", "Institution", "Intake", "Intervention", "Lead", "Medicine", "Meta-Analysis", "Molecular Genetics", "Monitor", "Morbidity - disease rate", "Negative Finding", "Nursing Homes", "Outcome", "Patient Recruitments", "Persons", "Population", "Pregnant Women", "Prevention", "Process", "Public Health", "Published Comment", "Randomized", "Recommended Daily Allowances", "Relative Risks", "Research", "Research Subjects", "Research Training", "Resources", "Respiratory Tract Infections", "Risk", "Science", "Scientist", "Skin", "Social Justice", "Source", "Suggestion", "Sun Exposure", "Technology", "Testing", "Toxic effect", "Training", "Translational Research", "Trust", "Uncertainty", "Universities", "Ventilator", "Viral Respiratory Tract Infection", "Vision", "Vitamin D", "Vitamin D Deficiency", "Vitamins", "Work", "base", "bone", "clinical practice", "compare effectiveness", "convict", "coronavirus disease", "design", "disorder risk", "dosage", "effective intervention", "experimental study", "falls", "high risk", "immunoregulation", "improved", "improved outcome", "innovation", "interest", "metropolitan", "mortality", "multidisciplinary", "population health", "precision medicine", "preference", "prevent", "secondary analysis", "seroconversion", "side effect", "social determinants", "success", "synergism", "translational medicine", "translational pipeline", "willingness" ], "approved": true } }, { "type": "Grant", "id": "7489", "attributes": { "award_id": "3UL1TR002389-04S2", "title": "ITM 2.0: Advancing Translational Science in Metropolitan Chicago", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-06", "end_date": "2022-06-30", "award_amount": 672852, "principal_investigator": { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23290, "first_name": "Lainie Friedman", "last_name": "Ross", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23291, "first_name": "Julian", "last_name": "Solway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.", "keywords": [ "2019-nCoV", "Academic Medical Centers", "Advocate", "Antiviral resistance", "Area", "Award", "Biotechnology", "COVID-19", "Characteristics", "Chicago", "Clinical", "Clinical Data", "Clinical Research", "Clinical Sciences", "Collaborations", "Communities", "Complex", "Data", "Databases", "Diagnosis", "Disease", "Drug Targeting", "Ethics", "Exposure to", "Failure", "Genomics", "Goals", "Health", "Health Personnel", "Healthcare", "Home environment", "Illinois", "Individual", "Industry", "Infection", "Infrastructure", "Institutes", "Institution", "Intervention", "Lead", "Link", "Maps", "Medical", "Modeling", "Molecular Genetics", "Morbidity - disease rate", "Outcome", "Patients", "Pharmaceutical Preparations", "Phylogenetic Analysis", "Procedures", "Process", "Public Health", "Published Comment", "Recording of previous events", "Research", "Research Training", "Resources", "Route", "Science", "Scientist", "Series", "Severities", "Social Justice", "Technology", "Testing", "Training", "Translational Research", "Trust", "Universities", "Variant", "Viral", "Virus Diseases", "Vision", "Work", "clinical practice", "convict", "demographics", "design", "disorder risk", "genetic variant", "genomic epidemiology", "improved", "innovation", "interest", "metropolitan", "mortality", "multidisciplinary", "novel", "pandemic disease", "precision medicine", "predict clinical outcome", "pressure", "social determinants", "success", "synergism", "translational medicine", "translational pipeline", "transmission process", "viral genomics", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "7490", "attributes": { "award_id": "3UL1TR002389-04S3", "title": "ITM 2.0: Advancing Translational Science in Metropolitan Chicago", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-06", "end_date": "2022-06-30", "award_amount": 1741474, "principal_investigator": { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23290, "first_name": "Lainie Friedman", "last_name": "Ross", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23291, "first_name": "Julian", "last_name": "Solway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.", "keywords": [ "Academic Medical Centers", "Acute", "Advocate", "Anti-Inflammatory Agents", "Award", "Biotechnology", "COVID-19", "Case Series", "Cessation of life", "Chicago", "Chronic", "Clinical Research", "Clinical Sciences", "Collaborations", "Communities", "Consumption", "Data", "Diet", "Disease", "Dose", "Eating", "Effectiveness", "Elderly", "Ethics", "Exposure to", "Failure", "Fishes", "General Population", "Goals", "Health", "Health Personnel", "Healthcare", "Home environment", "Hospitalization", "Hour", "Human", "Hypercalcemia", "Illinois", "Industry", "Infection", "Inflammatory", "Infrastructure", "Institute of Medicine (U.S.)", "Institutes", "Institution", "Intake", "Intervention", "Lead", "Medicine", "Meta-Analysis", "Molecular Genetics", "Monitor", "Morbidity - disease rate", "Negative Finding", "Nursing Homes", "Outcome", "Patient Recruitments", "Persons", "Population", "Pregnant Women", "Prevention", "Process", "Public Health", "Published Comment", "Randomized", "Recommended Daily Allowances", "Relative Risks", "Research", "Research Subjects", "Research Training", "Resources", "Respiratory Tract Infections", "Risk", "Science", "Scientist", "Skin", "Social Justice", "Source", "Suggestion", "Sun Exposure", "Technology", "Testing", "Toxic effect", "Training", "Translational Research", "Trust", "Uncertainty", "Universities", "Ventilator", "Viral Respiratory Tract Infection", "Vision", "Vitamin D", "Vitamin D Deficiency", "Vitamins", "Work", "base", "bone", "clinical practice", "compare effectiveness", "convict", "coronavirus disease", "design", "disorder risk", "dosage", "effective intervention", "experimental study", "falls", "high risk", "immunoregulation", "improved", "improved outcome", "innovation", "interest", "metropolitan", "mortality", "multidisciplinary", "population health", "precision medicine", "preference", "prevent", "secondary analysis", "seroconversion", "side effect", "social determinants", "success", "synergism", "translational medicine", "translational pipeline", "willingness" ], "approved": true } }, { "type": "Grant", "id": "7491", "attributes": { "award_id": "3UL1TR002389-04S4", "title": "ITM 2.0: Advancing Translational Science in Metropolitan Chicago", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-06", "end_date": "2022-06-30", "award_amount": 228225, "principal_investigator": { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23290, "first_name": "Lainie Friedman", "last_name": "Ross", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23291, "first_name": "Julian", "last_name": "Solway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.", "keywords": [ "Academic Medical Centers", "Advocate", "Award", "Biotechnology", "Chicago", "Clinical Research", "Clinical Sciences", "Collaborations", "Communities", "Computerized Medical Record", "Data", "Data Set", "Disease", "Ethics", "Failure", "Goals", "Health", "Health Personnel", "Healthcare", "Home environment", "Illinois", "Industry", "Infrastructure", "Institutes", "Institution", "Intervention", "Lead", "Molecular Genetics", "Morbidity - disease rate", "Outcome", "Process", "Public Health", "Published Comment", "Research", "Research Training", "Resources", "Science", "Scientist", "Social Justice", "Technology", "Testing", "Training", "Translational Research", "Trust", "Universities", "Vision", "Work", "clinical practice", "cohort", "convict", "coronavirus disease", "disorder risk", "improved", "innovation", "interest", "metropolitan", "mortality", "multidisciplinary", "precision medicine", "social determinants", "success", "synergism", "translational medicine", "translational pipeline" ], "approved": true } }, { "type": "Grant", "id": "7489", "attributes": { "award_id": "3UL1TR002389-04S2", "title": "ITM 2.0: Advancing Translational Science in Metropolitan Chicago", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-06", "end_date": "2022-06-30", "award_amount": 672852, "principal_investigator": { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23290, "first_name": "Lainie Friedman", "last_name": "Ross", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23291, "first_name": "Julian", "last_name": "Solway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.", "keywords": [ "2019-nCoV", "Academic Medical Centers", "Advocate", "Antiviral resistance", "Area", "Award", "Biotechnology", "COVID-19", "Characteristics", "Chicago", "Clinical", "Clinical Data", "Clinical Research", "Clinical Sciences", "Collaborations", "Communities", "Complex", "Data", "Databases", "Diagnosis", "Disease", "Drug Targeting", "Ethics", "Exposure to", "Failure", "Genomics", "Goals", "Health", "Health Personnel", "Healthcare", "Home environment", "Illinois", "Individual", "Industry", "Infection", "Infrastructure", "Institutes", "Institution", "Intervention", "Lead", "Link", "Maps", "Medical", "Modeling", "Molecular Genetics", "Morbidity - disease rate", "Outcome", "Patients", "Pharmaceutical Preparations", "Phylogenetic Analysis", "Procedures", "Process", "Public Health", "Published Comment", "Recording of previous events", "Research", "Research Training", "Resources", "Route", "Science", "Scientist", "Series", "Severities", "Social Justice", "Technology", "Testing", "Training", "Translational Research", "Trust", "Universities", "Variant", "Viral", "Virus Diseases", "Vision", "Work", "clinical practice", "convict", "demographics", "design", "disorder risk", "genetic variant", "genomic epidemiology", "improved", "innovation", "interest", "metropolitan", "mortality", "multidisciplinary", "novel", "pandemic disease", "precision medicine", "predict clinical outcome", "pressure", "social determinants", "success", "synergism", "translational medicine", "translational pipeline", "transmission process", "viral genomics", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "7490", "attributes": { "award_id": "3UL1TR002389-04S3", "title": "ITM 2.0: Advancing Translational Science in Metropolitan Chicago", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-06", "end_date": "2022-06-30", "award_amount": 1741474, "principal_investigator": { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23290, "first_name": "Lainie Friedman", "last_name": "Ross", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23291, "first_name": "Julian", "last_name": "Solway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.", "keywords": [ "Academic Medical Centers", "Acute", "Advocate", "Anti-Inflammatory Agents", "Award", "Biotechnology", "COVID-19", "Case Series", "Cessation of life", "Chicago", "Chronic", "Clinical Research", "Clinical Sciences", "Collaborations", "Communities", "Consumption", "Data", "Diet", "Disease", "Dose", "Eating", "Effectiveness", "Elderly", "Ethics", "Exposure to", "Failure", "Fishes", "General Population", "Goals", "Health", "Health Personnel", "Healthcare", "Home environment", "Hospitalization", "Hour", "Human", "Hypercalcemia", "Illinois", "Industry", "Infection", "Inflammatory", "Infrastructure", "Institute of Medicine (U.S.)", "Institutes", "Institution", "Intake", "Intervention", "Lead", "Medicine", "Meta-Analysis", "Molecular Genetics", "Monitor", "Morbidity - disease rate", "Negative Finding", "Nursing Homes", "Outcome", "Patient Recruitments", "Persons", "Population", "Pregnant Women", "Prevention", "Process", "Public Health", "Published Comment", "Randomized", "Recommended Daily Allowances", "Relative Risks", "Research", "Research Subjects", "Research Training", "Resources", "Respiratory Tract Infections", "Risk", "Science", "Scientist", "Skin", "Social Justice", "Source", "Suggestion", "Sun Exposure", "Technology", "Testing", "Toxic effect", "Training", "Translational Research", "Trust", "Uncertainty", "Universities", "Ventilator", "Viral Respiratory Tract Infection", "Vision", "Vitamin D", "Vitamin D Deficiency", "Vitamins", "Work", "base", "bone", "clinical practice", "compare effectiveness", "convict", "coronavirus disease", "design", "disorder risk", "dosage", "effective intervention", "experimental study", "falls", "high risk", "immunoregulation", "improved", "improved outcome", "innovation", "interest", "metropolitan", "mortality", "multidisciplinary", "population health", "precision medicine", "preference", "prevent", "secondary analysis", "seroconversion", "side effect", "social determinants", "success", "synergism", "translational medicine", "translational pipeline", "willingness" ], "approved": true } }, { "type": "Grant", "id": "7491", "attributes": { "award_id": "3UL1TR002389-04S4", "title": "ITM 2.0: Advancing Translational Science in Metropolitan Chicago", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-06", "end_date": "2022-06-30", "award_amount": 228225, "principal_investigator": { "id": 23289, "first_name": "Joshua J", "last_name": "Jacobs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23290, "first_name": "Lainie Friedman", "last_name": "Ross", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23291, "first_name": "Julian", "last_name": "Solway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.", "keywords": [ "Academic Medical Centers", "Advocate", "Award", "Biotechnology", "Chicago", "Clinical Research", "Clinical Sciences", "Collaborations", "Communities", "Computerized Medical Record", "Data", "Data Set", "Disease", "Ethics", "Failure", "Goals", "Health", "Health Personnel", "Healthcare", "Home environment", "Illinois", "Industry", "Infrastructure", "Institutes", "Institution", "Intervention", "Lead", "Molecular Genetics", "Morbidity - disease rate", "Outcome", "Process", "Public Health", "Published Comment", "Research", "Research Training", "Resources", "Science", "Scientist", "Social Justice", "Technology", "Testing", "Training", "Translational Research", "Trust", "Universities", "Vision", "Work", "clinical practice", "cohort", "convict", "coronavirus disease", "disorder risk", "improved", "innovation", "interest", "metropolitan", "mortality", "multidisciplinary", "precision medicine", "social determinants", "success", "synergism", "translational medicine", "translational pipeline" ], "approved": true } }, { "type": "Grant", "id": "7492", "attributes": { "award_id": "3R21AI147057-02S1", "title": "Mechanistic understanding and inhibition of Zika NS5 protein", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 10523, "first_name": "Mindy I.", "last_name": "Davis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-07-01", "end_date": "2021-06-30", "award_amount": 253310, "principal_investigator": { "id": 23292, "first_name": "Rong", "last_name": "Hai", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1190, "ror": "", "name": "UNIVERSITY OF CALIFORNIA RIVERSIDE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23293, "first_name": "Jikui", "last_name": "Song", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1190, "ror": "", "name": "UNIVERSITY OF CALIFORNIA RIVERSIDE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Mechanistic understanding and inhibition of Zika NS5 protein ABSTRACT Zika virus (ZIKV) belongs to the single-stranded RNA-containing flavivirus family. Its recent outbreak and implication in human diseases (e.g. neurological disorders) have raised a global health alarm, and urgency to develop a therapeutic strategy against ZIKV infection. However, there are no currently approved antivirals against ZIKV available yet. This application seeks to develop an antiviral strategy against the non-structural protein 5 (NS5) of ZIKV, which is responsible for virus-specific genomic replication. On one hand, the currently identified flavivirus inhibitors will be evaluated for their efficiency on ZIKV inhibition. On the other hand, mechanistic details of ZIKV NS5-mediated RNA replication will be investigated, thereby providing a basis for development of synergistic inhibition strategies targeting various enzymatic steps of ZIKV NS5. In Aim 1, structural, biochemical and cellular approaches will be taken to evaluate the inhibition of ZIKV NS5-mediated de novo RNA synthesis by the thiophenyl propargyl alcohol (TPA) compounds, the non-nucleoside inhibitors (NNIs) that have been identified as inhibitors for Dengue virus (DENV) NS5, in vitro and ex vivo. Our recent structural study of ZIKV NS5 revealed that the TPA-binding site of DENV NS5 is conserved in ZIKV NS5. Through evaluation of the inhibitory effects of the TPA compounds on ZIKV NS5, this application will address whether the TPA compounds can serve as inhibitors to ZIKV NS5, and more importantly, to provide a basis for structure-based drug optimization for ZIKV NS5. In Aim 2, the mechanistic basis of ZIKV NS5-mediated RNA replication will be determined through structure elucidation of the replication initiation and elongation complexes of ZIKV NS5, combined with mutational and enzymatic analyses. The structural knowledge on the conformational transition of ZIKV NS5 from replication initiation to elongation will then provide a framework for structure-based drug design for comprehensive inhibition of ZIKV NS5 activity. Together, the proposed studies will provide key mechanistic insights into the NS5-mediated genome replication and establish a foundation for development of effective inhibitors against ZIKV.", "keywords": [ "Address", "Adult", "Antiviral Agents", "Arboviruses", "Binding Sites", "Biochemical", "Biological Assay", "Complex", "Crystallization", "Dengue Virus", "Development", "Disease Outbreaks", "Drug Design", "Evaluation", "Family", "Fetus", "Flaviviridae", "Flavivirus", "Foundations", "Genome", "Genomics", "Goals", "Guillain-Barré Syndrome", "Health", "In Vitro", "Infection", "Knowledge", "Lead", "Ligands", "Link", "Mediating", "Methods", "Molecular Conformation", "Mutation", "Neurologic", "Nonstructural Protein", "Pharmaceutical Preparations", "Phase", "Proteins", "Protocols documentation", "RNA", "RNA chemical synthesis", "RNA replication", "RNA-Directed RNA Polymerase", "Replication Initiation", "Research", "Resistance", "Resolution", "South America", "Structure", "Therapeutic", "Titrations", "Vaccines", "Viral", "Virus", "Virus Diseases", "Virus Inhibitors", "Virus Replication", "ZIKA", "ZIKV infection", "Zika Virus", "arthropod-borne", "base", "conformational conversion", "design", "experimental study", "global health", "human disease", "inhibitor/antagonist", "insight", "lead optimization", "member", "mutant", "nervous system disorder", "novel", "novel therapeutics", "propargyl alcohol", "small molecule", "structural biology", "virology" ], "approved": true } }, { "type": "Grant", "id": "7493", "attributes": { "award_id": "3R21AI147057-01S1", "title": "Mechanistic understanding and inhibition of Zika NS5 protein", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 10523, "first_name": "Mindy I.", "last_name": "Davis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-11", "end_date": "2021-06-30", "award_amount": 57686, "principal_investigator": { "id": 23292, "first_name": "Rong", "last_name": "Hai", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1190, "ror": "", "name": "UNIVERSITY OF CALIFORNIA RIVERSIDE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23293, "first_name": "Jikui", "last_name": "Song", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1190, "ror": "", "name": "UNIVERSITY OF CALIFORNIA RIVERSIDE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Mechanistic understanding and inhibition of Zika NS5 and SARS-CoV-2 RdRP proteins ABSTRACT Zika virus (ZIKV) and Coronavirus (CoV) are single-stranded RNA viruses that pose grave threat to public health. In the first two decades of the 21st century, the global community has already witnessed one outbreak of Flavivirus, Zika virus (ZIKV), and three zoonotic outbreaks of CoV– severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) in 2002, the Middle East respiratory syndrome (MERS)-CoV in 2012, and the most recent, the novel SARS-CoV-2. These viruses are highly transmissible, greatly impacting the social, societal and economic dynamics. However, there are currently no approved drugs for either ZIKV or for zoonotic CoV, raising an urgent need for development of novel therapeutic strategies against ZIKV and CoV infection. This application seeks to develop an antiviral strategy targeting the viral core replication machinery, RNA-dependent RNA polymerase (RdRP), non-structural protein 5 (NS5) of ZIKV and non- structural protein 12 (NSP12) of SARS-CoV-2. On one hand, the currently identified small molecule inhibitors will be evaluated for their efficiency on ZIKV or SARS-CoV-2 inhibition. On the other hand, mechanistic details of ZIKV NS5 and SARS-CoV-2 RdRP-mediated RNA replication will be investigated, thereby providing a basis for development of synergistic inhibition strategies targeting various enzymatic steps of ZIKV NS5 and SARS- CoV-2. In Aim 1, structural, biochemical and cellular approaches will be taken to evaluate the inhibition of ZIKV NS5- or SARS-CoV-2 RdRP-mediated de novo RNA synthesis by candidate inhibitors. Through evaluation of the inhibitory effects of the candidate inhibitors on ZIKV NS5 or SARS-CoV-2 RdRP, this application will address whether these compounds can serve as inhibitors to ZIKV NS5 or SARS-CoV-2, and more importantly, to provide a basis for structure-based drug optimization for ZIKV NS5 or SARS-CoV-2. In Aim 2, the mechanistic basis of ZIKV NS5 and SARS-CoV-2 RdRP-mediated RNA replication will be determined through structure elucidation of the replication complexes of ZIKV NS5 or SARS-CoV-2 RdRP, combined with enzymatic analyses. The structural knowledge on the replication complexes of ZIKV NS5 and SARS-CoV-2 RdRP will then provide a framework for structure-based drug design for comprehensive inhibition of ZIKV NS5 and SARS-CoV-2 infection. Together, the proposed studies will provide key mechanistic insights into the viral RdRP-mediated genome replication and establish a foundation for development of effective inhibitors against ZIKV and SARS-CoV-2.", "keywords": [ "2019-nCoV", "Address", "Antiviral Agents", "Biochemical", "Biological Assay", "Clinical", "Communities", "Complex", "Coronavirus", "Coronavirus Infections", "Crystallization", "Dengue Virus", "Development", "Disease Outbreaks", "Drug Design", "Economics", "Evaluation", "Family", "Flavivirus", "Foundations", "Genome", "Genomics", "Goals", "Health", "In Vitro", "Infection", "Knowledge", "Ligands", "Mediating", "Methods", "Middle East Respiratory Syndrome Coronavirus", "Molecular Conformation", "Nonstructural Protein", "Pharmaceutical Preparations", "Phase", "Proteins", "Public Health", "RNA", "RNA Viruses", "RNA chemical synthesis", "RNA replication", "RNA-Directed RNA Polymerase", "Reporting", "Research", "SARS coronavirus", "STAT2 gene", "Structure", "Therapeutic", "Titrations", "Viral", "Virus", "Virus Diseases", "Virus Inhibitors", "Virus Replication", "ZIKA", "ZIKV infection", "Zika Virus", "Zoonoses", "base", "coronavirus disease", "design", "experimental study", "global health", "inhibitor/antagonist", "insight", "lead optimization", "member", "novel", "novel therapeutics", "propargyl alcohol", "remdesivir", "small molecule inhibitor", "social", "structural biology", "transcription factor", "viral RNA", "virology" ], "approved": true } }, { "type": "Grant", "id": "7495", "attributes": { "award_id": "3U01DA041048-06S1", "title": "8/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT CHLA", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 21593, "first_name": "Bethany", "last_name": "Deeds", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-09-30", "end_date": "2027-03-31", "award_amount": 180234, "principal_investigator": { "id": 23294, "first_name": "Megan Marie", "last_name": "Herting", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1555, "ror": "https://ror.org/00412ts95", "name": "Children's Hospital of Los Angeles", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23295, "first_name": "ELIZABETH R", "last_name": "SOWELL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1555, "ror": "https://ror.org/00412ts95", "name": "Children's Hospital of Los Angeles", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Adolescent Brain Cognitive Development (ABCD) study is the largest long-term study of child health and brain development in the US, consisting of a Coordinating Center, a Data Analysis and Informatics Resource Center, and 21 research sites. The ABCD Study has enrolled a diverse cohort of 11,878 9-10-year-olds and will continue to track their biological and behavioral development through adolescence into young adulthood. All participants receive neuroimaging, neuropsychological testing, bioassays, and detailed youth and parent assessments of substance use, mental health, physical health, and culture and environment. In March 2020, when our participants were ages 11-13, the world became substantially affected by the COVID-19 pandemic, leading to an upheaval in the economy and the lives of almost every family. Most U.S. schools closed to reduce viral spread. Many parents incurred changes in work (e.g., working-from-home, longer shifts, reduced wages, job loss). Some services and support systems became disrupted. And, the number of confirmed cases and deaths have continued to surge. The massive multifaceted impact of this unprecedented event has the potential to affect today’s children for decades to come. Here, we propose to leverage ABCD’s infrastructure, cohort, and existing protocol to rapidly characterize the impacts of the COVID-19 pandemic on each child in the study. In this proposal, we will capitalize on funded (NSF; PI Tapert) and pending supplements to administer queries to all ABCD participants and their parents about the impact of the pandemic on their lives (family level impact) by also incorporating publicly and privately available measures of community-level COVID-19 impacts. For participants’ neighborhoods (e.g., census tract, county, state), we will geocode measures of incidence, spatial distancing, changes in (un)employment, and timing of implementation of state and/or local policies on mitigation practices. By collecting this situational information at the family and community levels as soon as possible, we can use existing ABCD data to examine perturbations in developmental trajectories of brain functioning, cognition, substance use, academic achievement, social functioning, and physical and mental health. Specifically, we will (1) focus on characterizing the nature and variability of the community and regional impact of COVID-19, based on geocoding of ABCD participants’ neighborhoods (i.e., current home address) and (2) determine how community-level and family-level impacts of COVID-19 differentially influence stress, cognition, and mental health during and after the pandemic. We will analyze (1) the interactions between family- and community-specific impacts on ABCD participants’ immediate stress and mental health during the pandemic, (2) the extent to which such potential impacts are associated with each other, and (3) how both community and family factors (e.g., SES, neighborhood characteristics) may serve as protective factors. This unprecedented crisis provides an opportunity to exploit ABCD’s infrastructure and scientific rigor to discern critical dimensions of development not previously envisioned.", "keywords": [ "10 year old", "Academic achievement", "Acute", "Address", "Administrative Supplement", "Adolescence", "Adolescent", "Adolescent Development", "Adopted", "Affect", "Age", "Alcohol or Other Drugs use", "Area", "Behavioral", "Biological", "Biological Assay", "Brain", "COVID-19", "COVID-19 pandemic", "Cellular Phone", "Censuses", "Cessation of life", "Characteristics", "Child", "Child Health", "Chronic stress", "Cognition", "Collection", "Communities", "Coronavirus", "County", "Data", "Data Analyses", "Data Collection", "Development", "Dimensions", "Disasters", "Economics", "Employment", "Enrollment", "Environment", "Event", "Exposure to", "Family", "Funding", "Home environment", "Incidence", "Income", "Individual", "Infection", "Infrastructure", "Intervention", "Lead", "Link", "Longitudinal Studies", "Measurement", "Measures", "Mental Health", "Moods", "Movement", "National Institute of Drug Abuse", "Nature", "Neighborhoods", "Neuropsychological Tests", "Occupations", "Outcome", "Parents", "Participant", "Patient Self-Report", "Pattern", "Policies", "Population Density", "Prevalence", "Prevention", "Protocols documentation", "Questionnaires", "Reporting", "Research", "Research Project Grants", "Resource Informatics", "Risk", "Risk Factors", "Schools", "Services", "Shock", "Site", "Social Distance", "Social Functioning", "Socioeconomic Status", "Source", "Stress", "Structure", "Support System", "Unemployment", "United States", "Variant", "Viral", "Wages", "Work", "Youth", "base", "cognitive development", "cohort", "experience", "infrastructure development", "lower income families", "mortality", "neuroimaging", "pandemic disease", "payment", "physical conditioning", "protective factors", "resilience", "response", "young adult" ], "approved": true } } ], "meta": { "pagination": { "page": 1394, "pages": 1397, "count": 13961 } } }